CTX — Crescita Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$14.71m
- CA$8.50m
- CA$21.12m
Brief: Crescita Therapeutics Announces Appointment Of Serge Verreault As President & CEO
Brief: Crescita Therapeutics Receives First Shipments Of Pliaglis, Product Will Be Launched By U.S. Licensing Partner
Brief: Crescita Therapeutics Q4 Net Loss Per Share $0.59
Brief: Crescita Therapeutics says Jose Darocha appointed CFO
Brief: Knight Therapeutics announces increase in ownership of Crescita Therapeutics
Brief: Crescita Therapeutics reports positive topline results of phase 2 clinical trial to treat plaque psoriasis
Brief: Knight Therapeutics amended its secured loan agreement with Crescita Therapeutics
Brief: Crescita Therapeutics announces amended loan agreement with Knight Therapeutics
Brief: Crescita Therapeutics announces acquisition of Alyria skincare products
Brief: Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis
Brief: Crescita Therapeutics announces the appointment of a new president
Brief: Crescita Therapeutics net loss for three months ended Dec. 31, 2016 was $4.1 mln
Brief: Crescita therapeutics announces 2016 fourth quarter and year-end results
Brief: Crescita Therapeutics says signed a license agreement with a U.S.-based dermatological contract research company
Brief: Crescita Therapeutics names Muneerah Kanji as interim CFO
Brief: Crescita Therapeutics announces launch of Isdin product line
Brief: Crescita Therapeutics total revenue $1.1 mln versus $29,000 last year
Brief: Crescita appoints Dan Chicoine as interim CEO
Brief: Crescita Therapeutics announces changes to the board